Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Article Tools

• Email

  Thank you for your interest in spreading the word about Science Signaling.

  NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

  Your Email

  Your Name

  Send To

  Enter multiple addresses on separate lines or separate them with commas.

  You are going to email the following Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

  Message Subject (Your Name) has forwarded a page to you from Science Signaling

  Message Body (Your Name) thought you would like to see this page from the Science Signaling web site.

  Your Personal Message

  Send Message
• Download Powerpoint
• Print
• Save to my folders

  Log In with your AAAS Login

   

• Alerts

  Please log in to add an alert for this article.

  Log In with your AAAS Login

   

  Sign In to Email Alerts with your Email Address

  Email

  Log in
• Citation tools

  Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

  By Emiliano Cocco, F. Javier Carmona, Pedram Razavi, Helen H. Won, Yanyan Cai, Valentina Rossi, Carmen Chan, James Cownie, Joanne Soong, Eneda Toska, Sophie G. Shifman, Ivana Sarotto, Peter Savas, Michael J. Wick, Kyriakos P. Papadopoulos, Alyssa Moriarty, Richard E. Cutler Jr., Francesca Avogadri-Connors, Alshad S. Lalani, Richard P. Bryce, Sarat Chandarlapaty, David M. Hyman, David B. Solit, Valentina Boni, Sherene Loi, José Baselga, Michael F. Berger, Filippo Montemurro, Maurizio Scaltriti

  Science Signaling09 Oct 2018

  Metastatic breast cancer patients with coexistent HER2 mutation and amplification respond to neratinib.

  Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
• Share

  Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

  By Emiliano Cocco, F. Javier Carmona, Pedram Razavi, Helen H. Won, Yanyan Cai, Valentina Rossi, Carmen Chan, James Cownie, Joanne Soong, Eneda Toska, Sophie G. Shifman, Ivana Sarotto, Peter Savas, Michael J. Wick, Kyriakos P. Papadopoulos, Alyssa Moriarty, Richard E. Cutler Jr., Francesca Avogadri-Connors, Alshad S. Lalani, Richard P. Bryce, Sarat Chandarlapaty, David M. Hyman, David B. Solit, Valentina Boni, Sherene Loi, José Baselga, Michael F. Berger, Filippo Montemurro, Maurizio Scaltriti

  Science Signaling09 Oct 2018

  Metastatic breast cancer patients with coexistent HER2 mutation and amplification respond to neratinib.

  Share This Article: Copy